Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tularemia ("rabbit plague")]

Dieter Hassler, Tino F Schwarz, Rüdiger Braun

    Deutsche Medizinische Wochenschrift (1946)
    |February 25, 2003
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5-6 Years After Primary Vaccination in Adults ≥50 Years.

    Open forum infectious diseases·2026
    Same author

    [STIKO Recommendation: MF59-Adjuvanted Influenza Vaccine for Individuals ≥ 60 Years of Age].

    Deutsche medizinische Wochenschrift (1946)·2026
    Same author

    Current Advances in Preclinical Patient-Derived Cultivation Models for Individualized Drug Response Prediction in Pancreatic Cancer.

    Oncology research·2026
    Same author

    Novel L1CAM-antibody drug conjugates exert potent anti-tumor activity in preclinical models of even advanced pancreatic cancer.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
    Same author

    Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
    Same author

    Immune persistence and safety of the AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.

    Human vaccines & immunotherapeutics·2025